Cat. No. | Product name | CAS No. |
DC10501 |
G1T28(Trilaciclib)
Featured
G1T28(Trilaciclib) is a potential first-in-class, short-acting IV CDK4/6 inhibitor being developed to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. |
1374743-00-6 |
DC10153 |
GDC-0077
Featured
GDC-0077 is an orally available PI3K inhibitor with potential antineoplastic activity. GDC-0077 is extracted from patent WO 2017001645 A1, formula I. |
2060571-02-8 |
DC9592 |
GDC-0941 (dimethanesulfonate)
GDC-0941 2 MeSO3H salt is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold). |
957054-33-0 |
DC1054 |
GDC0941(Pictilisib)
Featured
GDC-0941 is a potent inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ with IC50 of 3 nM, 33 nM, 3 nM and 75 nM, respectively. |
957054-30-7 |
DC5081 |
Apitolisib
Featured
GDC-0980 (RG7422) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM, respectively. Also a mTOR inhibitor with Ki of 17 nM, and highly selective versus others PIKK family kinases. |
1032754-93-0 |
DC5107 |
SB-715992 (Ispinesib)
Featured
Ispinesib (SB 715992) is a potent mitotic kinesin KSP (Eg5) inhibitor with a Ki and an IC50 of 0.6 and 4.1 nM, respectively. |
336113-53-2 |
DCAPI1510 |
Ixabepilone
Featured
Ixabepilone (Azaepothilone B; BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound with clinical activity in a range of solid tumors. |
219989-84-1 |
DC9272 |
K 858
Featured
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics. |
72926-24-0 |
DCAPI1512 |
Lapatinib
Featured
Lapatinib |
231277-92-2 |
DC3143 |
Lapatinib ditosylate
Featured
Lapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
388082-78-8 |
DC9433 |
Lapatinib (ditosylate)
Lapatinib ditosylate(GW-572016 ditosylate) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. |
388082-77-7 |
DC10755 |
LSZ-102
Featured
LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. |
2135600-76-7 |
DC10987 |
LTX-315
This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
1345407-05-7 |
DC9836 |
Mivebresib(ABBV-075)
Featured
Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. |
1445993-26-9 |
DC7211 |
Neratinib (HKI-272)
Featured
Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR, respectively. |
698387-09-6 |
DC8021 |
Indoximod (NLG-8189)
Featured
NLG-8189 is an inhibitor of IDO and INDOL1 (IDO2) |
110117-83-4 |
DC9936 |
NMS-P118
Featured
NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor with excellent ADME and pharmacokinetic profiles and high efficacy in vivo. |
1262417-51-5 |
DC4118 |
NVP-BEP800
Featured
NVP-BEP800 is a novel, fully synthetic HSP90β inhibitor with IC50 of 58 nM. |
847559-80-2 |
DC8248 |
Ostarine(MK-2286)
Featured
Ostarine(MK-2866; GTX-024)A modulator to human androgen receptor. |
841205-47-8 |
DC8469 |
Palbociclib
Featured
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. |
571190-30-2 |
DC5067 |
Palbociclib (PD0332991 HCl)
Featured
Palbociclib is an oral, small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, now in Phase 3 clinical development for advanced breast cancer. |
827022-32-2 |
DC7704 |
Poziotinib
Featured
Poziotinib, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity. |
1092364-38-9 |